ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

ALC vs ABBV // FORWARD P/E MULTIPLE

Alcon Inc. (NYSE) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: ALC 4 — ABBV 10
▲ FORWARD P/E MULTIPLE LEADER: ALC
forward-pe
30.5x
forward-pe
113.1x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ALC VS. ABBV) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC ALC ABBV SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 41.00% 70.20% -29.20 ABBV /gross-margins <GO>
Return on Invested Capital (ROIC) 9.90% 29.00% -19.10 ABBV /roic <GO>
EV/EBITDA & P/E Valuation 21.0x 33.3x -12.30 ALC /valuation <GO>
Free Cash Flow Yield 2.21% 3.47% -1.26 ABBV /fcf-yield <GO>
Operating Margin 13.90% 24.60% -10.70 ABBV /operating-margins <GO>
Net Profit Margin 10.90% 6.90% +4.00 ALC /net-margins <GO>
Revenue Growth (YoY) -3.30% 8.60% -11.90 ABBV /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 2.27% -2.27 ABBV /dividend-safety <GO>
Altman Z-Score & Debt/Equity 3.74 5.33 -1.59 ABBV /balance-sheet <GO>
Piotroski F-Score Quality 7/9 7/9 0.00 TIE /piotroski-score <GO>
Options Implied Move & Put/Call Skew 6.90% 7.40% -0.50 ALC /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 67.7 72.8 -5.05 ABBV /rsi-technicals <GO>
10Y Yield & FRED Macro Beta 1.00 1.15 -0.15 ABBV /macro-sensitivity <GO>
Forward P/E Multiple ACTIVE 30.5x 113.1x -82.60 ALC /forward-pe <GO>
Enterprise Scale & Market Cap $35.54B $513.86B -$478.32B ABBV /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR ALC REV ABBV REV ALC GROSS % ABBV GROSS % ALC FCF ABBV FCF
FY 2025 — $61.16B — 70.2% — $17.82B
FY 2024 — $56.33B — 70.0% — $17.83B
FY 2023 — $54.32B — 44.0% — $20.39B
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ALC // BETA 1.00
ABBV // BETA 1.15